1. ALLA AKTIER
  2. NYHETER
  3. COMBIGENE

Combigene

Nyheter Combigene Nyheter alla bolag

Interim report January – June 2023 for CombiGene AB (publ)

MARKN.

April – June 2023
• Net sales: TSEK 1,788 (4,738).
• Other operating revenues: TSEK 1,413 (9,800).
• Profit from financial items: TSEK -6,286 (4,516).
• Earnings per share: SEK -0.32 (0.23).

January – June 2023
• Net sales: TSEK 3,955 (16,141).
• Other operating revenues: TSEK 543 (12,602).
• Profit from financial items: TSEK -20,903 (1,832).
• Earnings per share: SEK -1.06 (0.09).
• Cash and cash equivalents: TSEK 115,442 (125,953).

Events during the period
• Gene Therapy, one of Nature’s journals, publishes an article about CombiGene’s epilepsy project authored by Esbjörn Melin, scientist at CombiGene.
• High activity level in the pain program COZY in preparation of the final preclinical toxicology program in the peptide project COZY01.
• CombiGene to play an integral part in the development of a national infrastructure for ATMPs. CombiGene’s CEO Jan Nilsson elected Chairman of the Board of CCRM Nordic AB.
• CombiGene forms prominent Scientific Advisory Board within the pain program COZY.
• Jan Nilsson leaves his position as CEO of CombiGene – COO Peter Ekolind takes over as new CEO on September 1, 2023.

Events after the end of the period
• There have been no significant events after the end of the period.

Contacts

CombiGene AB (publ)
Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
jan.nilsson@combigene.com

www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
+46-8-357355 info@combigene.com

About CombiGene

CombiGene’s vision is to offer patients affected by severe life‐changing diseases opportunities for a better life through innovative gene therapies. CombiGene’s business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to preclinical/clinical concept verification. Drug candidates for common diseases will be co‐developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in‐house for medicines aimed at limited patient populations. 

The company has an exclusive collaboration and license agreement with Spark Therapeutics for the CG01 project and a collaboration agreement with the Danish company Zyneyro within the pain program COZY. 
 
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, info@fnca.se.

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282.
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714

Attachments

CombiGene Q2 2023 EN

Datum 2023-08-25, kl 09:00
Källa MFN
Bifogade filer
CombiGene Q2 2023 EN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!